Improving patient care now and for future generations.

Wills Eye Retina specialists are in the forefront of research efforts, participating in multiple clinical trials to investigate new forms of treatment for macular degeneration, diabetic retinopathy, and a variety of other retinal conditions.



These new medical compounds are being studied to determine their efficacy and safety in comparison to the current standard anti-VEGF agents. Administered by intravitreal injection, they may potentially achieve a longer therapeutic effect.

PDS is a small surgical implant that is intended to slowly release ranibizumab, a well-established anti-VEGF medication. The aim is to reduce the need for intravitreal injections and the implant can be refilled with a special syringe in the office setting.

These technologies utilize different non-disease-causing viral vectors to carry and deliver a coding sequence for a soluble anti-VEGF protein. In essence the goal is for anti-VEGF medication to be manufactured by cells in the eye, which will hopefully reduce the need for frequent intravitreal injections.

Wills Eye researchers are committed to providing access to new treatments and have been the principal investigators of most of the major clinical trials in retina. For several, we are the only center involved nationwide.

Neo-Vascular (Wet) Age-Related Macular Degeneration



For information, call 215-928-3092

Dry Age-Related Macular Degeneration


Inflammation is implicated in the pathophysiology of atrophy and vision cell loss in advanced dry AMD. Pharmacologic agents designed to block or modulate various parts of the inflammation process may slow the progression and development of geographic atrophy.


Cell based therapy involves the subretinal surgical delivery of stem cells to replace or regenerate dysfunctional cells and tissue caused by dry AMD.


As our collective understanding about the complex genetics behind the development of advanced dry AMD continues to increase, therapeutic agents will likely begin to target specific sub-types or genetic variants of dry AMD. 

Diabetic Retinopathy / Diabetic Macular Edema




A multi-center, non-randomized, open-label, multiple ascending dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of Ro7200220 in monotherapy and in combination with ranibizumab following intravitreal administration in patients with diabetic macular edema.

A study assessing AR-13503 implant alone and in combination with Aaflibercept in subjects with nAMD or DME.

Learn more.

This study will evaluate the efficacy, safety, and pharmacokinetics of the Port Delivery System with ranibizumab in participants with diabetic macular edema compared with intravitreal ranibizumab (Pagoda)

Learn more.

Retinal Vein Occlusion

Novartis Pharmaceuticals*

Novartis Pharmaceuticals*

Assessing the efficacy and safety of brolucizumab versusaflibercept in patients with visual impairment due to macular edema secondary to Central Retinal Vein Occlusion (RAVEN)

Learn more.

Assessing the efficacy and safety of brolucizumab versusaflibercept in patients with visual impairment due to macular edema secondary to Branch Retinal Vein Occlusion (RAPTOR)

Learn more.

View Current Wet Macular Degeneration Clinical TrialsView Current Dry Macular Degeneration Clinical Trials